MedTrace Logo

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT06035393 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2025-12-22

No results posted yet for this study

Summary

This is a randomized, double blind, double dummy, active-controlled, parallel-group study to assess the efficacy and Safety of HRG2005 inhalation in patients with moderate to severe chronic obstructive pulmonary disease. Approximately 200 patients with moderate to severe COPD will be randomized into the study.

Conditions

Interventions

DRUG

HRG2005 inhalation

Drug 1: dose 1; dose 2; dose 3

DRUG

Placebo to match HRG2005 inhalation

Drug 2

DRUG

Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Drug 3

DRUG

Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Drug 4

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2025-02-17
Completion
2025-02-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06035393 on ClinicalTrials.gov